Resumo

OVIEDO, Gabriel Fernando et al. Metabolic Control, Evaluation and Follow-up Interventions in Patients With Schizophrenia. rev.colomb.psiquiatr. [online]. 2015, vol.44, n.4, pp.220-229. ISSN 0034-7450.  https://doi.org/10.1016/j.rcp.2015.05.008.

Objectives: To determine the laboratory tests, related to metabolic risk that should be practiced to adult patients diagnosed with schizophrenia. To assist the clinician decision-making process about complementary diagnostic evaluation strategies in adult diagnosed with schizophrenia. Methods: A clinical practice guideline was elaborated under the parameters of the Met hodological Guide of the Ministerio de Salud y Protección Social to identify, synthesize and evaluate the evidence and make recommendations about the treatment and follow-up of adult patients with schizophrenia. The evidence of NICE guide 82 was adopted and updated. The evidence was presented to the Guideline Developing Group and recommendations, employing the GRADE system, were produced. Results: The risk of overall mortality in schizophrenia is higher than in the general population excluding suicide. Results related with mortality associated to antipsychotics showed contradictory results. Metabolic outcomes showed a higher incidence and association with schizophrenia and treatment with antipsychotics (AP). The diagnosis of dyslipidemia in men with schizophrenia appears to be lower in comparison with the general population. However, changes in weight, blood sugar levels, HDL cholesterol and triglycerides are influenced by the use of antipsychotics in general there is a higher risk of developing diabetes mellitus in adults with schizophrenia. Conclusion: Based on the evidence found a plan was formulated for the evaluation of physiological and paraclinical variables during and before the management with AP in adult diagnosed with schizophrenia. The overall quality of evidence is low considering that most of the reports come from observational studies that have risk of bias and some designs have methodological limitations.

Palavras-chave : Clinical Practice Guidelines; Schizophrenia; Metabolic risk.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )